- Home
- PEG vs ONC Comparison
PEG vs ONC Comparison
Compare PEG & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEG
- ONC
- Stock Information
- Founded
- PEG 1903
- ONC 2010
- Country
- PEG United States
- ONC Switzerland
- Employees
- PEG N/A
- ONC N/A
- Industry
- PEG Power Generation
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- PEG Utilities
- ONC Health Care
- Exchange
- PEG Nasdaq
- ONC Nasdaq
- Market Cap
- PEG 42.6B
- ONC 34.8B
- IPO Year
- PEG N/A
- ONC N/A
- Fundamental
- Price
- PEG $84.02
- ONC $314.12
- Analyst Decision
- PEG Buy
- ONC Strong Buy
- Analyst Count
- PEG 12
- ONC 10
- Target Price
- PEG $92.27
- ONC $350.00
- AVG Volume (30 Days)
- PEG 2.7M
- ONC 229.1K
- Earning Date
- PEG 11-03-2025
- ONC 11-06-2025
- Dividend Yield
- PEG 3.01%
- ONC N/A
- EPS Growth
- PEG 20.00
- ONC N/A
- EPS
- PEG 3.96
- ONC N/A
- Revenue
- PEG $11,134,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- PEG $13.25
- ONC $887.89
- Revenue Next Year
- PEG $5.35
- ONC $22.45
- P/E Ratio
- PEG $21.15
- ONC N/A
- Revenue Growth
- PEG 8.69
- ONC 47.33
- 52 Week Low
- PEG $74.67
- ONC $170.99
- 52 Week High
- PEG $95.22
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- PEG 54.53
- ONC 43.26
- Support Level
- PEG $82.63
- ONC $310.46
- Resistance Level
- PEG $86.09
- ONC $319.57
- Average True Range (ATR)
- PEG 1.82
- ONC 8.41
- MACD
- PEG 0.31
- ONC -3.20
- Stochastic Oscillator
- PEG 65.33
- ONC 11.64
About PEG Public Service Enterprise Group Incorporated
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.